Does Lurbinectedin Interact with Other Drugs?
Yes, lurbinectedin (brand name Zepzelca), used to treat metastatic small cell lung cancer, has known drug interactions that can lead to adverse reactions. It is metabolized primarily by CYP3A4 enzymes and is a substrate for P-glycoprotein (P-gp) transporters, increasing risks when combined with inhibitors, inducers, or substrates of these pathways.[1][2]
Common Interactions and Risks
Strong CYP3A4 inhibitors like ketoconazole, itraconazole, or ritonavir can raise lurbinectedin levels, potentially causing severe myelosuppression, fatigue, or nausea. Strong CYP3A4 inducers such as rifampin or carbamazepine reduce its effectiveness by lowering exposure.[1] P-gp inhibitors (e.g., cyclosporine) may increase toxicity, while P-gp substrates (e.g., digoxin) face altered levels.[2]
| Interaction Type | Examples | Potential Adverse Effects |
|------------------|----------|---------------------------|
| CYP3A4 Inhibitors | Ketoconazole, ritonavir | Increased toxicity (e.g., bone marrow suppression, gastrointestinal issues) |
| CYP3A4 Inducers | Rifampin, phenytoin | Reduced efficacy, treatment failure |
| P-gp Inhibitors | Cyclosporine, verapamil | Elevated lurbinecteddin levels, organ toxicity |
| Substrates (CYP3A4/P-gp) | Midazolam, digoxin | Altered pharmacokinetics of co-administered drug |
Avoid concurrent use where possible; dose adjustments or monitoring are recommended.[1]
How to Manage Interactions in Practice
Check patient medications for CYP3A4 or P-gp involvement before starting lurbinectedin. Use tools like the Liverpool Drug Interactions database for real-time checks. For unavoidable combinations, monitor blood counts, liver function, and drug levels closely. No specific antidote exists for overdoses from interactions.[2]
Special Cases: Chemotherapy and Supportive Drugs
Lurbinectedin is often given with supportive agents like dexamethasone (a mild CYP3A4 inducer), which has minimal impact at standard doses. Interactions with other chemotherapies (e.g., topotecan) are not well-studied but may amplify myelotoxicity due to overlapping effects. Proton pump inhibitors like omeprazole (weak CYP3A4 interactions) require caution.[1]
What Patients Should Watch For
Symptoms of adverse interactions include worsening fatigue, unexplained bruising, severe nausea, or infections. Report new medications (including herbals like St. John's wort, a CYP3A4 inducer) to oncologists immediately. No major food interactions noted, but grapefruit juice should be avoided as a CYP3A4 inhibitor.[2]
[1]: Zepzelca Prescribing Information (FDA)
[2]: Drugs.com - Lurbinectedin Interactions